Insparin Therapeutics Appoints Dr. Alex Gaidamaka as Chief Technology Officer
FOR IMMEDIATE RELEASE: Houston, TX — Sep-23-2025 — Insparin Therapeutics, a biotechnology company developing insulin-independent therapies for severe insulin resistance syndromes, announced today the appointment of Dr. Alex Gaidamaka, Ph.D., D.V.M., as its new Chief Technology Officer, effective immediately. Dr. Gaidamaka brings more than 30 years of biopharmaceutical industry experience, with deep expertise across all…